The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease
Antioxidants · 03.06.2026 · 15 (6) · 710
DOI: 10.3390/antiox15060710 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 03.06.2026. Verfasst von Adrián Róbert Gál und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 270 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Fund of Hungary.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a highly prevalent multisystem disorder and is strongly associated with increased cardiovascular risk. Cardiovascular diseases represent the leading cause of mortality in this population. As the hepatic manifestation of systemic metabolic dysfunction, MASLD is initiated by excess lipid accumulation driven by increased dietary fatty acid intake and accelerated de novo lipogenesis. This triglyceride overload induces lipotoxicity, triggering hepatocellular injury, immune activation, and mitochondrial dysfunction. Excessive mitochondrial reactive oxygen species (ROS) generation acts as a critical second hit, promoting inflammatory cytokine production and disease progression. Beyond lipid dysregulation, impaired hepatic insulin signaling leads to hyperglycemia and compensatory hyperinsulinemia, further stimulating lipogenesis and reinforcing a self-perpetuating metabolic cycle. Persistent ROS production overwhelms antioxidant defenses and depletes hepatic glutathione (GSH), resulting in systemic redox imbalance. These disturbances extend beyond the liver, contributing to atherogenic dyslipidemia and chronic inflammation. In parallel, gut dysbiosis and increased intestinal permeability amplify immune activation. Reduced circulating GSH further weakens systemic antioxidant capacity; oxidative stress may represent a central mechanistic link between MASLD and CVD. In concert with metabolic and inflammatory mediators, ROS disrupt pathways governing vascular and myocardial homeostasis, leading to coronary atherosclerosis, microvascular dysfunction, left ventricular remodeling, hypertrophy, and impaired relaxation. Clinically, this translates into an increased burden of coronary artery disease and heart failure, particularly heart failure with preserved ejection fraction. Given this integrated pathophysiology, early identification of subclinical cardiovascular involvement is essential. We highlight emerging biomarkers, advocate for multidisciplinary screening strategies, and discuss integrated pharmacological approaches targeting shared metabolic pathways. Recognizing MASLD as a cardiovascular risk amplifier is critical for improving risk stratification and enabling the development of effective, co-targeted therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.
- Multidisciplinary Medical and Engineering Cellular Bioimpedance Research Group, János Szentágothai Research Center, University of Pécs, 7624 Pécs, Hungary.
- Heart Institute, Medical School, University of Pécs, 7624 Pécs, Hungary.
- Molecular Cardiology Research Group, János Szentágothai Research Center, University of Pécs, 7624 Pécs, Hungary.
- John von Neumann Faculty of Informatics, Óbuda University, 1044 Budapest, Hungary.
- Bioimpedance Technologies Research Center, University Research and Innovation Center, Óbuda University, 1034 Budapest, Hungary.
ORCID-Profile: Adrián Róbert Gál, István Szokodi, Zoltán Vizvári, András Vereczkei
Förderung
- National Research, Development and Innovation Fund of Hungary
Zitieren
APA
Gál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A., Petykó, Z., Karádi, Z., & Tóth, A. (2026). The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease. Antioxidants, 15(6), 710. https://doi.org/10.3390/antiox15060710
Vancouver
Gál AR, Szokodi I, Vizvári Z, Győrfi N, Vereczkei A, Petykó Z, et al. The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease. Antioxidants. 2026;15(6):710. doi:10.3390/antiox15060710
BibTeX
@article{Gl2026,
author = {Gál, Adrián Róbert and Szokodi, István and Vizvári, Zoltán and Győrfi, Nina and Vereczkei, András and Petykó, Zoltán and Karádi, Zoltán and Tóth, Attila},
title = {The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {6},
pages = {710},
doi = {10.3390/antiox15060710}
}
EUVIMED